Sign In
24 Mar 2010 11:52
DEALINGS BY CONNECTED EXEMPT PRINCIPAL TRADERS
WITHOUT RECOGNISED INTERMEDIARY STATUS, OR WITH RI STATUS
BUT NOT DEALING IN A CLIENT-SERVING CAPACITY
(Rule 38.5(b) of the Takeover Code)
Ā
Ā
1. KEY INFORMATION
Ā
|
Name of exempt principal trader |
Piper Jaffray Ltd. |
|
Company dealt in |
Ark Therapeutics Group plcĀ |
| Class of relevant security to which the dealings being disclosed relate (Note 1) |
Ord 1p |
| Date of dealing |
23 March 2010 |
Ā
Ā
2. INTERESTS, SHORT POSITIONS AND RIGHTS TO SUBSCRIBE
Ā
(a) Interests and short positions (following dealing) in the class of relevant security dealt in (Note 2)
Ā
|
Ā Ā |
Long |
Short |
|
Ā Ā |
Number (%) |
Number (%) |
|
(1) Relevant securities Ā |
210,196 0.10% |
|
|
(2) Derivatives (other than options) Ā |
|
|
|
(3) Options and agreements to purchase/sell Ā |
|
|
|
Total Ā |
210,196 0.10% |
|
Ā
(b) Interests and short positions in relevant securities of the company, other than the class dealt in (Note 2)
Ā
|
Class of relevant security: Ā |
Long |
Short |
|
Ā Ā |
Number (%) |
Number (%) |
|
(1) Relevant securities Ā |
|
|
|
(2) Derivatives (other than options) Ā |
|
|
|
(3) Options and agreements to purchase/sell Ā |
|
|
|
Total Ā |
|
|
Ā
(c) Rights to subscribe (Note 2)
Ā
|
Class of relevant security:
Ā |
Details |
| Ā |
|
Ā
3. DEALINGS (Note 3)
Ā
(a) Purchases and sales
Ā
|
Purchase/sale Ā |
Number of securities |
Price per unit (Note 4) |
|
Buy |
10,000 |
11.50p |
|
Buy |
10,000 |
11.75p |
|
Buy |
10,000 |
12.00p |
Ā
Ā
(b) Derivatives transactions (other than options)
Ā
|
Product name, e.g. CFD |
Long/short (Note 5) |
Number of securities (Note 6) |
Price per unit (Note 4) |
|
Ā Ā |
|
|
|
Ā
Ā
Ā
(c) Options transactions in respect of existing securities
(i) Writing, selling, purchasing or varying
Ā
|
Product name, e.g. call option Ā |
Writing, selling, purchasing, varying etc. |
Number of securities to which the option relates (Note 6) |
Exercise price |
Type, e.g. American, European etc. |
Expiry date |
Option money paid/received per unit (Note 4) |
|
|
|
|
|
|
|
|
Ā
Ā
(ii) Exercising
Ā
|
Product name, e.g. call option |
Number of securities |
Exercise price per unit (Note 4) Ā |
|
|
|
Ā Ā |
Ā
(d) Other dealings (including new securities) (Note 3)
Ā
|
Nature of transaction (Note 7) Ā |
Details |
Price per unit (if applicable) (Note 4) |
|
Ā Ā |
|
|
Ā
Ā
4. OTHER INFORMATION
Ā
Agreements, arrangements or understandings relating to options or derivatives
Ā
Ā
|
Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated. |
|
Ā Ā Ā |
Ā
Ā
Is a Supplemental Form 38.5(b) attached? (Note 8) NO
Ā
Ā
| Date of disclosure |
24 March 2010 |
| Contact name |
Norman Gould |
| Telephone number |
020 3142 8780 |
|
Name of offeree/offeror with which connected |
Ark Therapeutics Group plcĀ |
| Nature of connection (Note 9) |
Adviser and broker |
Ā
Ā
Notes
Ā
The Notes on Form 38.5(b) can be viewed on the Takeover Panel's website at www.thetakeoverpanel.org.uk
Ā
Ā
Follow the stocks
